Stock Taper 
SI-BONE, Inc. develops minimally invasive implantable devices like iFuse and iFuse-3D to treat sacropelvic disorders and fractures globally, primarily through direct sales and distributors.
A 3D-printed titanium implant for sacroiliac joint fusion, enhancing spinal fusion surgeries, with recent expansions and breakthrough status addressing lumbopelvic fixation failures.
On January 12, 2026, SI-BONE announced preliminary full-year 2025 worldwide revenue of approximately $200.8 to $200.9 million, representing about 20% growth year-over-year. Despite what appeared to be strong top-line growth, the company's stock experienced a significant negative reaction, declining by 12.57% on the day of the announcement, which captured investor and analyst attention.
In 2025, SI-BONE demonstrated a significant strategic shift by consistently achieving positive adjusted EBITDA and reaching cash flow breakeven, signaling a successful transition to a profitable growth model. This was driven by the expansion of its product portfolio beyond the core SI joint fusion to a more comprehensive sacropelvic platform, leading to increased revenue guidance and a significant expansion of its active physician base.
Integer (NYSE: ITGR - Get Free Report) and SiBone (NASDAQ: SIBN - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership. Profitability This table compares Integer and SiBone's net margins, return
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 SYK | $274.44 | COMPARE |
 SNN | $26.89 | COMPARE |
 GMED | $73.39 | COMPARE |
 BFLY | $8.78 | COMPARE |
 ATEC | $10.25 | COMPARE |
 CNMD | $45.18 | COMPARE |
 INNV | $8.99 | COMPARE |
 PACB | $2.73 | COMPARE |
